Resources

An analytical immunology laboratory performs an Enzyme-Linked Immunosorbent Assay (ELISA) to monitor antibody titers in two clinical cohorts exposed to hepatitis A virus (HAV): Cohort 1 received intramuscular pooled human immune globulin (HNIG, passive immunization) 48 hours48\text{ hours} post-exposure; Cohort 2 received a two-dose inactivated HAV vaccine (active immunization) at 00 and 6 months6\text{ months}. Serum samples collected at t=1 montht = 1\text{ month}, t=6 monthst = 6\text{ months}, and t=24 monthst = 24\text{ months} are serially diluted (1:10,1:100,1:1,000,1:10,000,1:100,0001:10, 1:100, 1:1{,}000, 1:10{,}000, 1:100{,}000) to determine the endpoint titer (reciprocal of highest dilution with optical density OD450≥0.200\text{OD}_{450} \ge 0.200). (a) Predict the relative endpoint titers (e.g., High, Moderate, or Undetectable/Baseline) for Cohort 1 versus Cohort 2 at each of the three time points (1 mo1\text{ mo}, 6 mo6\text{ mo}, 24 mo24\text{ mo}). (b) Following an in vitro re-stimulation assay of peripheral blood mononuclear cells (PBMCs) isolated at t=24 monthst = 24\text{ months} with inactivated HAV antigen, identify which cohort will exhibit robust [3H]-thymidine\left[\text{}^3\text{H}\right]\text{-thymidine} incorporation (cell proliferation) and interferon-gamma (IFN-γ\text{IFN-}\gamma) secretion, and justify your answer based on memory cell establishment.

Answer and steps

Final answer

(a) Cohort 1 (Passive): at 1 month=Moderate (e.g., 1:100 to 1:1,000)1\text{ month} = \text{Moderate (e.g., } 1:100\text{ to } 1:1{,}000\text{)}, at 6 months=Undetectable/Baseline (<1:10)6\text{ months} = \text{Undetectable/Baseline } (< 1:10), at 24 months=Undetectable/Baseline (<1:10)24\text{ months} = \text{Undetectable/Baseline } (< 1:10). Cohort 2 (Active): at 1 month=Moderate (1:100 to 1:1,000)1\text{ month} = \text{Moderate } (1:100\text{ to } 1:1{,}000), at 6 months (post-boost)=High (≥1:10,000)6\text{ months (post-boost)} = \text{High } (\ge 1:10{,}000), at 24 months=High/Persistent (1:1,000 to 1:10,000)24\text{ months} = \text{High/Persistent } (1:1{,}000\text{ to } 1:10{,}000). (b) Only Cohort 2 will demonstrate significant [3H]-thymidine\left[\text{}^3\text{H}\right]\text{-thymidine} incorporation and IFN-γ\text{IFN-}\gamma secretion because active vaccination induced antigen-specific central and effector memory T cells and memory B cells capable of anamnestic reactivation; Cohort 1 received only donor immunoglobulins without host lymphocyte activation, leaving their PBMC population devoid of HAV-specific memory cells.

Steps

Antibody Titers Over Time

Mechanisms of Active vs. Passive Immunity

Immunity to pathogens can be acquired actively or passively, leading to distinct kinetics of antibody longevity and immunological memory:

  • Passive Immunity (Cohort 1): Involves the direct transfer of preformed exogenous immunoglobulins (e.g., pooled human normal immune globulin, HNIG).
    • The recipient's immune system is bypassed; endogenous B cells and T cells are not activated.
    • Circulating donor antibodies (primarily IgG\ce{IgG}) decay naturally according to their biological half-life (t1/2≈21–28 dayst_{1/2} \approx 21\text{–}28\text{ days}).
    • No immunological memory cells (memory B cells, memory T cells, or long-lived plasma cells) are formed.
  • Active Immunity (Cohort 2): Involves the administration of pathogen-derived antigens (e.g., inactivated hepatitis A virus vaccine).
    • Antigens are captured and presented by antigen-presenting cells (APCs) to naive helper T (CD4+\text{CD4}^+) cells, which stimulate antigen-specific B cells.
    • B cells undergo clonal selection, somatic hypermutation, affinity maturation, and class switching in germinal centers.
    • A primary dose induces moderate antibody production and primes memory cells. A booster dose at t=6 monthst = 6\text{ months} triggers a secondary (anamnestic) response, generating high titers of high-affinity antibodies and long-lived memory T and B cells.

Step-by-Step Derivation

  1. At t=1 montht = 1\text{ month}:

    • Cohort 1: Donor IgG\ce{IgG} has undergone approximately one half-life. A substantial fraction remains in circulation, yielding a Moderate titer (typically 1:100 to 1:1,0001:100\text{ to } 1:1{,}000).
    • Cohort 2: The primary immune response to the initial dose is fully developed, yielding a Moderate serum antibody titer (typically 1:100 to 1:1,0001:100\text{ to } 1:1{,}000).
  2. At t=6 monthst = 6\text{ months}:

    • Cohort 1: Over 5 to 65\text{ to }6 half-lives have elapsed since injection. The infused antibodies have been catabolized to negligible levels, resulting in an Undetectable/Baseline titer (<1:10< 1:10).
    • Cohort 2: Administration of the booster dose stimulates rapid differentiation of memory B cells into antibody-secreting plasma cells, producing a High endpoint titer (≥1:10,000\ge 1:10{,}000).
  3. At t=24 monthst = 24\text{ months}:

    • Cohort 1: Remains Undetectable/Baseline (<1:10< 1:10) because no host cells were programmed to synthesize anti-HAV antibodies.
    • Cohort 2: Bone marrow-resident long-lived plasma cells continue constitutive antibody secretion, maintaining a High/Persistent protective titer (typically 1:1,000 to 1:10,0001:1{,}000\text{ to } 1:10{,}000).

Cell Proliferation and Cytokine Secretion in Recall Assay

  • Proliferation ([3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine} incorporation): When peripheral blood mononuclear cells (PBMCs) containing antigen-specific memory T cells encounter the recall antigen in vitro, the T-cell receptors (TCRs) recognize HAV peptides displayed on MHC molecules. This stimulates clonal expansion; proliferating cells synthesize DNA and incorporate radioactive [3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine}.
  • Effector Cytokine (IFN-γ\text{IFN-}\gamma) Secretion: Activated memory CD4+\text{CD4}^+ (Th1\text{Th1}) and CD8+\text{CD8}^+ T cells rapidly secrete interferon-gamma (IFN-γ\text{IFN-}\gamma) to orchestrate antiviral defenses.
  • Comparison:

    • Cohort 2 will exhibit robust [3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine} incorporation and elevated IFN-γ\text{IFN-}\gamma release because the active vaccination established a pool of circulating HAV-specific memory T cells and memory B cells capable of immediate reactivation.
    • Cohort 1 will show no significant response above background. The passive infusion of antibodies conferred temporary humoral neutralization without priming host T or B lymphocytes, leaving the host's PBMC compartment devoid of HAV-specific memory cells.

Typical errors

OverviewACEpath Teacher's Diagnosis

01 The student confuses passive and active immunity mechanisms, incorrectly assuming passive antibody transfer confers long-term immunological memory.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Incorrect
  1. Step 1

    1 mo1\text{ mo}: Cohort 11 High, Cohort 22 Moderate   ⟹  6 mo\implies 6\text{ mo}: Cohort 11 Moderate, Cohort 22 Moderate   ⟹  24 mo\implies 24\text{ mo}: Cohort 11 High, Cohort 22 High

    Correct

    1 mo1\text{ mo}: Cohort 11 Moderate, Cohort 22 Moderate; 6 mo6\text{ mo}: Cohort 11 Undetectable/Baseline, Cohort 22 High; 24 mo24\text{ mo}: Cohort 11 Undetectable/Baseline, Cohort 22 High/Persistent

    You predicted that Cohort 11 maintains moderate titers at 6 months6\text{ months} and reaches high titers at 24 months24\text{ months}. In reality, passively transferred donor IgG\ce{IgG} has a biological half-life of approximately 21–28 days21\text{–}28\text{ days} and is cleared within a few months, becoming undetectable by 6 months6\text{ months}. For Cohort 22, the booster at 6 months6\text{ months} triggers an anamnestic response yielding a High titer that persists through 24 months24\text{ months}.

  2. Step 2

    Both Cohort 11 and Cohort 22 will exhibit proliferation and IFN-γ\text{IFN-}\gamma secretion. Receiving anti-HAV antibodies programs the recipient's immune system to remember HAV, leading to memory cell establishment and recall responses in both groups.

    Correct

    Only Cohort 22 will exhibit robust [3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine} incorporation and IFN-γ\text{IFN-}\gamma secretion. Active vaccination presents antigen to host lymphocytes, generating antigen-specific memory B and T cells. Passive administration of antibodies does not activate host B or T cells and creates zero immunological memory.

    You stated that receiving preformed antibodies programs the host immune system to establish memory cells. Passive transfer of immunoglobulins bypasses host antigen presentation and clonal selection, meaning Cohort 11 has no HAV-specific memory T or B cells to proliferate or secrete IFN-γ\text{IFN-}\gamma upon re-stimulation.

WHAT YOU DID WELL
Compliments from Your Teacher

You recognized that active vaccination in Cohort 2 leads to protective antibody production and memory cell recall.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Conflating passive antibody transfer with active immunological memory

Predicting an increase in Cohort 1 antibody titers at 24 months despite no secondary antigen exposure or vaccination.

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated passively transferred immunoglobulins as an active stimulus that educates host lymphocytes. Exogenous antibodies are simply circulating proteins that clear via natural catabolism; they do not trigger TCR/BCR engagement, clonal expansion, or differentiation into memory B or T cells.

REASONING PATH
Your ACEpath teacher’s suggested approach
Mechanisms of Immunity
  • Active immunity requires host exposure to antigen, stimulating clonal selection and memory cell generation. Passive immunity supplies preformed antibodies, providing immediate but transient protection without activating host lymphocytes.

  • Check whether the intervention administers an antigen (active) or preformed antibodies (passive) before predicting long-term titers or memory responses.

Antibody Half-Life vs. Sustained Titers
  • Injected IgG\ce{IgG} decays exponentially according to its half-life (t1/2≈21–28 dayst_{1/2} \approx 21\text{–}28\text{ days}) and reaches baseline within 4–6 months4\text{–}6\text{ months} unless host plasma cells actively synthesize new antibodies.

  • Model passive antibody levels as an exponential decay toward zero, reserving sustained or rising titers for hosts undergoing active B-cell responses.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Passive antibodies (Cohort 1) undergo exponential decay (t1/2≈3–4 weekst_{1/2} \approx 3\text{–}4\text{ weeks}): Moderate at 1 mo1\text{ mo}, Undetectable at 6 mo6\text{ mo}, Undetectable at 24 mo24\text{ mo}.

  2. Active vaccination (Cohort 2) primes naive cells by 1 mo1\text{ mo} (Moderate), mounts a robust secondary response following the 6 mo6\text{ mo} boost (High), and maintains titers via long-lived plasma cells at 24 mo24\text{ mo} (High/Persistent).

  3. In vitro PBMC recall with HAV antigen requires host memory T cells: only Cohort 2 possesses antigen-specific memory T cells to drive [3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine} incorporation and IFN-γ\text{IFN-}\gamma secretion.

Final answer

(a) Cohort 1: Moderate at 1 mo1\text{ mo}, Undetectable/Baseline at 6 mo6\text{ mo}, Undetectable/Baseline at 24 mo24\text{ mo}. Cohort 2: Moderate at 1 mo1\text{ mo}, High at 6 mo6\text{ mo}, High/Persistent at 24 mo24\text{ mo}. (b) Only Cohort 2 will exhibit proliferation and IFN-γ\text{IFN-}\gamma secretion because active immunization establishes antigen-specific memory T and B cells, whereas passive antibody infusion does not stimulate host lymphocyte memory.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the distinct cellular pathways of humoral immunity, noting why clonal expansion and germinal center reactions require antigen presentation rather than soluble antibody exposure.

  • Practice interpreting serological clearance curves for maternal or therapeutic IgG\ce{IgG} versus endogenous active vaccination curves.

OverviewACEpath Teacher's Diagnosis

02 The student misjudges the clearance kinetics of passive antibodies, believing injected IgG persists at high titers for years without a host cellular response.

Sample Student Work

Reviewed by ACEpath Teacher
Step-by-Step Review
Walk Through It with Your Teacher
Partially correct
  1. Step 1

    1 mo:Cohort 1 High, Cohort 2 Moderate  ⟹  6 mo:Cohort 1 High, Cohort 2 Moderate  ⟹  24 mo:Cohort 1 High, Cohort 2 High1\text{ mo}: \text{Cohort 1 High, Cohort 2 Moderate} \implies 6\text{ mo}: \text{Cohort 1 High, Cohort 2 Moderate} \implies 24\text{ mo}: \text{Cohort 1 High, Cohort 2 High}

    Correct

    Cohort 1 (Passive): 1 mo=Moderate1\text{ mo} = \text{Moderate}, 6 mo=Undetectable/Baseline6\text{ mo} = \text{Undetectable/Baseline}, 24 mo=Undetectable/Baseline24\text{ mo} = \text{Undetectable/Baseline}. Cohort 2 (Active): 1 mo=Moderate1\text{ mo} = \text{Moderate}, 6 mo=High6\text{ mo} = \text{High}, 24 mo=High/Persistent24\text{ mo} = \text{High/Persistent}.

    Passively infused donor IgG\text{IgG} has a serum half-life of only 21 to 28 days21\text{ to }28\text{ days} and is not renewed by host plasma cells, meaning Cohort 1 titers drop to undetectable levels by 6 months6\text{ months} and remain baseline at 24 months24\text{ months}. Furthermore, the scheduled booster dose given at 6 months6\text{ months} to Cohort 2 triggers an anamnestic secondary response, raising its titer to High at 6 months6\text{ months} rather than remaining Moderate.

  2. Step 2

    Cohort 2 will exhibit robust proliferation and IFN-γ\text{IFN-}\gamma secretion.   ⟹  \implies Active vaccination induces antigen-specific memory T cells and B cells, whereas passive immunoglobulin therapy transfers preformed antibodies without generating host memory cells.

WHAT YOU DID WELL
Compliments from Your Teacher

You correctly identified that only Cohort 2 will exhibit robust proliferation and cytokine release in the in vitro re-stimulation assay.

You clearly distinguished the fundamental difference in memory cell generation between active vaccination and passive antibody transfer.

THE ERROR
Where Your ACEpath Teacher Spotted the Mistake
Passive Antibody Clearance Kinetics

none

WHY IT HAPPENED
ACEpath Teacher's Diagnosis

You treated passively administered immunoglobulins as persistent circulating proteins over multi-year intervals, ignoring the natural catabolic half-life of IgG antibodies and the requirement of host plasma cells for ongoing antibody replenishment.

REASONING PATH
Your ACEpath teacher’s suggested approach
Biological Half-Life of Passive IgG
  • Exogenous antibodies are finite circulating proteins that decay exponentially according to their biological half-life (t1/2≈3–4 weekst_{1/2} \approx 3\text{--}4\text{ weeks}) without ongoing host synthesis.

  • Calculate elapsed half-lives for passive transfers: after 5 to 6 half-lives5\text{ to }6\text{ half-lives} (around 5–6 months5\text{--}6\text{ months}), residual donor antibody concentration falls below diagnostic thresholds (<1:10< 1:10).

Kinetics of Booster Immunization
  • A secondary (booster) antigen exposure rapidly activates primed memory B cells, generating a high-affinity, high-titer secondary antibody spike.

  • Recognize scheduled vaccine booster time points (such as dose 2 at 6 months6\text{ months}) as immediate catalysts for High antibody titers rather than static moderate levels.

CORRECTED PATH
ACEpath Teacher's Demonstration
  1. Evaluate Cohort 1 (Passive) over time: at 1 month1\text{ month}, donor IgG\text{IgG} has completed approximately one half-life (t1/2≈21–28 dayst_{1/2} \approx 21\text{--}28\text{ days}), leaving a Moderate titer (1:100 to 1:1,0001:100\text{ to } 1:1{,}000). By 6 months6\text{ months} and 24 months24\text{ months}, the donor immunoglobulins have been completely cleared by normal protein catabolism, resulting in Undetectable/Baseline titers (<1:10< 1:10).

  2. Evaluate Cohort 2 (Active) over time: at 1 month1\text{ month}, the primary response produces a Moderate titer (1:100 to 1:1,0001:100\text{ to } 1:1{,}000). At 6 months6\text{ months}, the second vaccine dose acts as an anamnestic booster, driving titers to High (≥1:10,000\ge 1:10{,}000). At 24 months24\text{ months}, long-lived plasma cells maintain a High/Persistent titer (1:1,000 to 1:10,0001:1{,}000\text{ to } 1:10{,}000).

  3. Retain your correct response for part (b): Cohort 2 exhibits robust [3H]-thymidine\left[{}^3\text{H}\right]\text{-thymidine} incorporation and IFN-γ\text{IFN-}\gamma secretion due to the reactivation of vaccine-induced memory T and B cells.

Final answer

(a) Cohort 1: 1 mo=Moderate1\text{ mo} = \text{Moderate}, 6 mo=Undetectable/Baseline6\text{ mo} = \text{Undetectable/Baseline}, 24 mo=Undetectable/Baseline24\text{ mo} = \text{Undetectable/Baseline}. Cohort 2: 1 mo=Moderate1\text{ mo} = \text{Moderate}, 6 mo=High6\text{ mo} = \text{High}, 24 mo=High/Persistent24\text{ mo} = \text{High/Persistent}. (b) Cohort 2, because active immunization primes host memory T and B cells, whereas passive immunization transfers transient antibodies without establishing memory cells.

NEXT STEPS
Final Takeaways from Your Teacher
  • Review the biological clearance curve of IgG antibodies versus the de novo synthesis curve of plasma cells over a multi-month timeline.

  • Practice sketching antibody titer curves that distinguish primary versus secondary anamnestic responses from passive immunoglobulin decay curves.

Lock it in

Similar question

01

A newborn acquires maternal IgG antibodies across the placenta against measles virus. At 15 months15\text{ months} of age, the child has not yet received the MMR vaccine. Predict whether the child possesses protective measles antibody titers at 15 months15\text{ months}, and explain why based on immunoglobulin kinetics.

Answer

The child will not have protective titers. Transplacentally transferred maternal IgG\ce{IgG} decays with a half-life of approximately 3–4 weeks3\text{–}4\text{ weeks} and becomes undetectable by 6–12 months6\text{–}12\text{ months}. Because passive transfer does not prime host infant B or T cells, no endogenous antibodies or memory cells remain.

02

Two individuals are exposed to rabies virus. Patient A receives rabies vaccine alone (active). Patient B receives both rabies immune globulin (RIG, passive) on day 0 and the full rabies vaccine series (active) on days 0, 3, 7, and 14. Compare their serum neutralizing antibody sources at day 2 versus day 90.

Answer

At day 2, Patient B has protective titers derived from the infused passive RIG, whereas Patient A has negligible titers because primary active B-cell activation takes 7–10 days7\text{–}10\text{ days}. At day 90, the RIG in Patient B has been catabolized, and both patients maintain protective titers synthesized entirely by endogenous long-lived plasma cells generated from active vaccination.

03

In an experimental trial, mice in Group X receive purified polyclonal anti-ovalbumin (OVA) antibodies, while mice in Group Y are immunized with OVA protein emulsified in alum adjuvant. Six months later, splenocytes from both groups are isolated and cultured with OVA peptide. Predict the relative concentrations of IL-2 and incorporation of BrdU (a thymidine analog) in the two splenocyte cultures.

Answer

Group Y splenocytes will show high IL-2 secretion and robust BrdU incorporation, reflecting clonal expansion of OVA-specific memory helper T cells primed by active immunization. Group X splenocytes will show background levels for both markers because passive antibody transfer never activated or expanded antigen-specific host T cells.

Loading workspace…